GE MEDICAL SYSTEMS

AI in Medicine Market to reach USD 156.8B by 2033, growing at 27.6% CAGR. Driven by AI tech advancements, personalized medicine, and chronic disease management, with North America leading in 2023. AI enhances diagnostics, treatment, and healthcare efficiency.

The AI in precision medicine market is projected to grow from USD 1.75B in 2024 to USD 37.60B by 2034, with a CAGR of 35.9%. Key segments include deep learning (33.7% share in 2024), software (41.6% share), oncology (31.0% revenue share), and neurology (fastest CAGR of 36.8%). North America leads with a 29.6% revenue share, while Europe is expected to grow at a CAGR of 36.3%. AI integration enhances personalized treatments, early disease detection, and drug development, driving market growth.

The AI in precision medicine market is expected to grow from USD 0.78 billion in 2024 to USD 3.92 billion by 2030, driven by personalized treatments, advanced genomics, and drug development acceleration. AI analyzes complex data for quicker disease identification and tailored therapies, optimizing diagnostics and treatment outcomes. Key players include NVIDIA, Google, Microsoft, and IBM, focusing on innovations like deep learning and AI platforms for drug discovery.

The cardiac implants market, valued at USD 38.1 billion in 2023, is projected to reach USD 79.2 billion by 2032, growing at a CAGR of 8.5%. Factors driving growth include the rising prevalence of cardiovascular diseases, an aging population, and advancements in medical technology. Governments and regulatory bodies are supporting market growth through investments and stringent regulations, enhancing patient confidence in cardiac implants.

The Precision Medicine market is projected to grow from $89.9B in 2023 to $161.1B by 2030, driven by tech advancements, declining genomic sequencing costs, and personalized treatments. Oncology, chronic diseases, and AI integration are key growth areas.

The global AI in diagnostics market was valued at USD 1.40 billion in 2024 and is projected to reach USD 10.15 billion by 2033. AI technologies enhance diagnostic accuracy and efficiency, with applications in radiology, pathology, cardiology, and cancer diagnosis. North America leads in market share, while Asia Pacific shows rapid growth due to government investments and rising chronic disease prevalence.

The AI in oncology market is expected to grow from USD 2.45 billion in 2024 to USD 11.52 billion by 2030, driven by cancer prevalence, early diagnosis, precision oncology, and drug discovery. Key players include Siemens Healthineers, GE Healthcare, and Medtronic, who use AI for early detection, diagnosis, and treatment planning. Siemens Healthineers offers AI-Rad Companion and Ethos Therapy, GE Healthcare supports AI tools for personalized treatment, and Medtronic launched GI Genius for colorectal cancer detection.

GE HealthCare unveiled over 40 innovations at RSNA 2024, focusing on AI integration and digital solutions to address healthcare challenges like staff burnout and precision medicine. Key innovations include Clarify DL, Aurora dual-head SPECT/CT system, and CareIntellect for Oncology. Mark Stoesz, President of Enterprise Solutions, emphasized the importance of understanding local needs and partnerships, particularly in the Asia-Pacific region, where GE HealthCare is investing in innovation and education to support emerging markets.

The Global Medical Isotope Market was valued at USD 5.66 billion in 2023 and is projected to reach USD 12.15 billion by 2032, growing at a CAGR of 8.87% driven by increased applications in diagnostics and therapy, particularly in cancer treatment. Key isotopes include technetium-99m, iodine-131, and lutetium-177. The market is influenced by advancements in nuclear medicine, imaging technologies, and personalized treatments, with challenges in supply chain and transportation due to radioactive nature. Major players include GE Healthcare, Jubilant Radiopharma, and Mallinckrodt Pharmaceuticals. North America dominates the market, while Asia-Pacific shows the fastest growth.

Polyethylene glycol (PEG) is crucial in medical applications, enhancing drug bioavailability and reducing immunogenicity. However, PEGylated nanopharmaceuticals have caused side effects, particularly after intravenous administration. PEG's mechanism of side effects is unclear but may involve immune response stimulation. Studies show PEG can induce cytokine production and neutrophil extracellular trap formation, potentially through Ca²⁺ signaling, highlighting the need for further research on PEG's immunological effects.